PTJ
IMUC

Paul Tudor Jones’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Paul Tudor Jones’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,253
Closed -$45K – 1737
2014
Q3 		$45K Buy
1,253
+239
+24% +$9.2K ﹤0.01% 1307
2014
Q2 		$45K Hold
1,014
– – ﹤0.01% 1125
2014
Q1 		$49K Sell
1,014
-644
-39% -$31.5K ﹤0.01% 1151
2013
Q4 		$61K Buy
+1,658
New +$157K ﹤0.01% 1230

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Paul Tudor Jones's IMUC Position: Q4 2014 in Review

Paul Tudor Jones sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2014, closing a stake of 1,253 shares — an estimated $45K sold.

Paul Tudor Jones first reported a position in IMUC in Q4 2013 and held it in 4 quarters. The position peaked at $61K in Q4 2013. 31 funds tracked by Wall St. Rank hold IMUC as of Q4 2014.

  • Paul Tudor Jones reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2014 after selling out during the quarter.
  • Paul Tudor Jones sold 1,253 ImmunoCellular Therapeutics, Ltd. shares in Q4 2014, an estimated $45K.
  • Paul Tudor Jones first reported a position in ImmunoCellular Therapeutics, Ltd. in Q4 2013 and held it in 4 quarters.
  • Paul Tudor Jones's ImmunoCellular Therapeutics, Ltd. position peaked at $61K in Q4 2013.
  • 31 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2014.

Based on Tudor Investment Corp's 13F filing for Q4 2014, filed 17 Feb 2015.